Michelle Gilson
Stock Analyst at Morgan Stanley
(1.11)
# 3,771
Out of 5,072 analysts
31
Total ratings
32.14%
Success rate
-6.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $6.42 | +211.53% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $79.40 | -62.22% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $9.72 | +74.90% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $212.33 | -7.69% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $35.41 | +27.08% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $30.91 | +145.88% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $55.93 | +62.70% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $6.42
Upside: +211.53%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $79.40
Upside: -62.22%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $9.72
Upside: +74.90%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $212.33
Upside: -7.69%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $35.41
Upside: +27.08%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $30.91
Upside: +145.88%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $55.93
Upside: +62.70%